Psyence Biomedical Advances Psilocybin Palliative Care Study
Company Announcements

Psyence Biomedical Advances Psilocybin Palliative Care Study

Psyence Group Inc. (TSE:PSYG) has released an update.

Psyence Group Inc’s associate, Psyence Biomedical, has received approval to begin a Phase IIb clinical trial in Melbourne, Australia, to explore the effects of nature-derived psilocybin on Adjustment Disorder in palliative care patients. The study will test various doses alongside psychotherapy, aiming to improve the quality of life for those with life-limiting illnesses. This research could represent a shift in palliative care treatment, addressing a significant unmet medical need.

For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskPsyence Group Sells Stake to Psyence Biomedical
TipRanks Canadian Auto-Generated NewsdeskPsyence Group Expands Psilocybin Clinical Trials
TipRanks Canadian Auto-Generated NewsdeskPsyence Group Enhances Liquidity with Equity Swap
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App